Director, AI/ML - Generative Foundation Models for Biotherapeutics
Eli Lilly and Company
Summary
At Lilly, we unite caring with discovery to make life better for people around the world. For more than 25 years, Lilly's Biotechnology Discovery Research (BioTDR) organization has advanced novel antibody and peptide therapeutics from concept through clinical development to market in areas of high unmet medical need. This role is based at the Lilly Biotechnology Center in San Diego, where we are expanding our computational capabilities to build a generative design platform. By bringing together AI/ML, protein engineering, automation, structural biology, and high-throughput experimentation, BioTDR is creating an integrated de novo design platform capable of generating, ranking, and optimizing novel therapeutic antibodies and other biotherapeutics with improved activity, safety, manufacturability, and target coverage. Designs are rapidly evaluated through experimental validation, creating a continuous learning cycle that strengthens both models and discovery outcomes. The program is supported by dedicated capacity on LillyPod, our wholly owned 1,016-GPU NVIDIA Blackwell Ultra SuperPOD. Help us push the de novo protein design frontier beyond binders to molecules that can become medicines, faster.
Job description
Primary Responsibilities
Our Generative Design platform has three pillars: Generative Foundation Models, Generative Protein Design & Optimization, and Active Learning & Design Validation. The Director of Generative Foundation Models will lead the development of protein and antibody foundation models and validate their performance against experimental outcomes, not just published baselines. You will be accountable for the program's generative model families end to end, across architecture choice, training strategy, and validation, and co-define the program's technical agenda with leadership. You will lead a team of AI researchers and ML infrastructure engineers while staying hands-on and giving direct technical guidance on every model in your workstream.
- Lead generative AI and protein foundation model development, driving state-of-the-art machine learning approaches for representation learning, generative protein design, sequence-structure-function modeling, and multimodal biological learning.
- Set training strategy, developing the pre-training and fine-tuning approach for your models across architecture choice, model family, training curriculum, and evaluation.
- Devise training infrastructure, designing and steering the training lifecycle and scaling approach against LillyPod capacity, accountable for reproducibility, checkpointing, and throughput, with the ML infrastructure engineers on your team.
- Direct confidence and calibration work, treating it as a first-class research objective and reducing the gap between model-ranked and experimentally validated design performance.
- Drive model improvement, resolving underperforming models to root cause across architecture, data, and execution, and making timely decisions to retrain, pivot, or discontinue.
- Drive the advancement of foundation model portfolio, establishing success metrics and ensuring progress translates into measurable experimental outcomes.
- Leverage multimodal and proprietary biological data, creating differentiated learning advantages by bringing proprietary sequence, structure, binding, functional, developability, and other biological measurements into model development.
- Lead a high-performing team and provide scientific and technical leadership, recruiting and developing AI researchers and engineers on your team and providing sustained technical mentorship. Guide model architecture choices, experimental design, technical prioritization, and research direction while remaining sufficiently close to the science and technology to challenge assumptions and identify new opportunities.
- Evaluate and incorporate external innovation, staying current with rapidly evolving advances in foundation models, generative AI, protein design, structural modeling, and related technologies. Evaluate external methods and collaborations and determine when to build, adapt, or partner.
- Communicate scientific strategy and impact, presenting technical progress, experimental validation, key learnings, and strategic recommendations to scientific leadership and broader R&D stakeholders. Contribute to publications, external collaborations, and scientific presentations where appropriate.
Requirements
- Ph.D. in computer science, mathematics, physics, computational biology, or a related quantitative field
- 3+ years of relevant research experience following the Ph.D. (or an M.S. with 6+ years)
- Experience as technical lead of a multi-person modeling effort
- First-author or equivalently attributable contribution to structure-based generative model
- Track record of carrying projects end to end
- Experience training deep learning models on multi-node infrastructure
- Strong Python and PyTorch
Benefits
- 401(k)
- Pension
- Vacation benefits
- Medical, Dental & Vision
- Prescription drug benefits
- Flexible spending accounts
- Life insurance
- Death benefits
- Employee assistance program
- Fitness benefits
- Employee clubs and activities
- Company bonus
Company overview
Eli Lilly and Company, commonly known as Lilly, is a leading American multinational pharmaceutical corporation headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company has grown into one of the world's most valuable pharmaceutical enterprises, with operations in approximately 125 countries. Lilly specializes in developing and manufacturing innovative medicines across multiple therapeutic areas, including diabetes, oncology, neuroscience, immunology, and cardiometabolic diseases. The company is renowned for its groundbreaking work in insulin production, having been the first to mass-produce insulin and later developing the first commercially available insulin product in the U.S. Lilly's current portfolio includes blockbuster medications such as Mounjaro and Zepbound (tirzepatide) for diabetes and obesity, Trulicity (dulaglutide) for type 2 diabetes, Verzenio (abemaciclib) for breast cancer, and Taltz (ixekizumab) for autoimmune conditions. With approximately 47,000 employees worldwide, Lilly maintains a strong commitment to research and development, investing heavily in scientific innovation to address some of the world's most significant health challenges. The company operates with a mission to make life better for people around the world through the discovery and delivery of innovative medicines.